Update on the STEADFAST study: In June 2015, Horizon Pharma, LLC launched a Phase 3 study of Actimmune in individuals with FA, ages 10-25 years. The study is now past the halfway mark for enrollment with 48 of 90 individuals enrolled. We hope to have all 90 subjects enrolled by mid-year of 2016. Individuals who were enrolled in June are now completing the double blind placebo portion of the study and entering the open label extension study.
Thank you to everyone in the FA community who is participating in the study.
For more information about this trial and sites participating visit, www.curefa.org/active-clinical-trials.